1
|
Nikoghosyan S, Alevizopoulos A, Ahmad SN, Aldemir E, Arjomandi Rad A, Vardanyan R. Outcomes of robotic-assisted radical nephrectomy during service implementation: Lessons from an audit. Scott Med J 2025; 70:19-24. [PMID: 39925024 DOI: 10.1177/00369330251314079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2025]
Abstract
BackgroundRobot-assisted surgery (RAS) is an extension of minimally invasive surgery rapidly gaining acceptance in many conditions. The study aims to assess and share lessons impact of RAS on the radical nephrectomy (RN) service during the implementation phase.MethodsTwo separate analyses were carried out: to compare the outcome of all RN - before and after the implementation of RAS regardless of surgical mode, and a direct comparison between two minimal invasive approaches: Robotic-assisted radical nephrectomies (RARNs) and Laparoscopic radical nephrectomies (LRNs).ResultsThe study included 55 pre- and 45 robotic era RNs: 45 RARNs, 48 LRNs and 7 open radical nephrectomies (ORNs). Following RAS implementation, all RNs transitioned to RARNs. The broader comparison of all RNs in the robotic versus pre-robotic periods revealed significant reductions in estimated blood loss and the length of hospital stay, though operative times were notably longer. In the direct comparison between LRNs and RARNs, no major differences in perioperative outcomes were noted, except for a significantly longer duration of surgery in the RARN group.ConclusionThe introduction of the robotic platform resulted in a paradigm shift in RN service, eliminating ORN and LRN. Despite increasing operative duration, RARNs improved certain perioperative outcomes (specifically length of stay and blood loss) and were favoured over other modalities.
Collapse
Affiliation(s)
- Samvel Nikoghosyan
- Department of Urology, United Lincolnshire Teaching Hospitals Trust, Lincoln, UK
| | | | - Sheikh Nissar Ahmad
- Department of Urology, United Lincolnshire Teaching Hospitals Trust, Lincoln, UK
| | - Ezgi Aldemir
- School of Medicine, The University of Nottingham, Nottingham, UK
| | | | - Robert Vardanyan
- Department of Medicine, Faculty of Medicine, Imperial College London, London, UK
| |
Collapse
|
2
|
Naughton A, Ryan ÉJ, Keenan R, Thomas AZ, Smyth LG, Manecksha RP, Flynn RJ, Casey RG. Surgical Approach for Partial Nephrectomy in the Management of Small Renal Masses: A Systematic Review and Network Meta-Analysis. J Endourol 2024; 38:358-370. [PMID: 38149582 DOI: 10.1089/end.2023.0107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2023] Open
Abstract
Background: A variety of surgical and nonsurgical management options for small renal masses (SRMs) now exist. Surgery in the form of partial nephrectomy (PN) has three different approaches. It is unclear which PN approach, if any, offers superior clinical outcomes. Aim: The aim of this study is to compare outcomes in patients with SRMs <4 cm undergoing PN through the open partial nephrectomy (OPN), laparoscopic partial nephrectomy (LPN), or robotic partial nephrectomy (RPN) approach and to establish the advantages and disadvantages of the various approaches. Methods: A systematic literature search was conducted for studies comparing at least two of the above techniques. Eighteen studies and 17,013 patients were included in our study. A network meta-analysis with a frequentist framework was performed. OPN was used as the baseline comparator. The prespecified primary outcome was R0 resection rates. Secondary outcomes included operating time, ischemia time, blood loss, transfusion rates, urine leak rates, significant morbidity, length of stay, and recurrence. Results: There was no significant difference between the techniques in terms of R0 rates, tumor recurrence, urine leak rates, renal function, and >3a Clavien-Dindo complications. LPN had a longer ischemic time and operating time. OPN had a longer length of stay and higher average intraoperative blood loss. RPN had lower blood transfusion rates. Discussion: All approaches are acceptable from an oncological perspective. The minimally invasive approaches (i.e., RPN and LPN) offer advantages in terms of morbidity; however, LPN may increase ischemic time and operative duration. Variations between perioperative outcomes may influence the choice of approach on a case-by-case and institutional basis.
Collapse
Affiliation(s)
- Ailish Naughton
- Department of Urology, Tallaght University Hospital, Dublin, Ireland
| | - Éanna J Ryan
- Department of Surgery, Tallaght University Hospital, Dublin, Ireland
| | - Robert Keenan
- Department of Urology, Tallaght University Hospital, Dublin, Ireland
| | - Arun Z Thomas
- Department of Urology, Tallaght University Hospital, Dublin, Ireland
- Department of Surgery, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Lisa G Smyth
- Department of Urology, Tallaght University Hospital, Dublin, Ireland
- Department of Surgery, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Rustom P Manecksha
- Department of Urology, Tallaght University Hospital, Dublin, Ireland
- Department of Surgery, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Robert J Flynn
- Department of Urology, Tallaght University Hospital, Dublin, Ireland
- Department of Surgery, School of Medicine, Trinity College Dublin, Dublin, Ireland
| | - Rowan G Casey
- Department of Urology, Tallaght University Hospital, Dublin, Ireland
| |
Collapse
|
3
|
Mendes G, Madanelo M, Vila F, Versos R, Teixeira BL, Rocha MA, Mesquita S, Marques-Monteiro M, Príncipe P, Ramires R, Lindoro J, Fraga A, Silva-Ramos M. Transperitoneal vs. Retroperitoneal Approach in Laparoscopic Partial Nephrectomy for Posterior Renal Tumors: A Retrospective, Multi-Center, Comparative Study. J Clin Med 2024; 13:701. [PMID: 38337397 PMCID: PMC10856370 DOI: 10.3390/jcm13030701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Revised: 01/18/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024] Open
Abstract
Purpose: The aim of our study is to compare the perioperative, functional, and oncological outcomes of laparoscopic transperitoneal partial nephrectomy (LTPN) and laparoscopic retroperitoneal partial nephrectomy (LRPN) for posterior cT1 renal tumors. Methods: We retrospectively collected data on all patients who consecutively underwent LTPN and LRPN for posterior cT1 renal tumors in three different centers from January 2015 to January 2023. Patients with a single, unilateral, cT1 renal mass, located in the posterior renal surface were included. Patients' data regarding perioperative, functional, and oncological outcomes were collected from medical records and statistically analyzed and compared. Results: A total of 128 patients was obtained, with 53 patients in the LPTN group and 75 patients in the LRPN group. Baseline characteristics were similar. Warm ischemia time (WIT) (18.8 vs. 22.6 min, p = 0.002) and immediate postoperative eGFR drop (-6.1 vs. -13.0 mL/min/1.73 m2, p = 0.047) were significantly lower in the LPTN group. Estimated blood loss (EBL) (100 vs. 150 mL, p = 0.043) was significantly lower in the LRPN group. All other perioperative and functional outcomes and complications were similar between the groups. The positive surgical margin (PSM) rate was lower in the LRPN group, although without statistical significance (7.2% vs. 13.5%, p = 0.258). Surgical success defined by Trifecta (WIT ≤ 25 min, no PSM, and no major postoperative complication) was similar between both approaches. Conclusions: LTPN has significantly shorter WIT and a significantly smaller drop in immediate eGFR when compared to LRPN for posterior renal tumors. On the other hand, LRPN has significantly less EBL than LTPN. LRPN demonstrated fewer PSMs than LTPN, albeit without statistical significance. In terms of overall surgical success, as defined by Trifecta, both approaches achieved similar results.
Collapse
Affiliation(s)
- Gonçalo Mendes
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Mariana Madanelo
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Fernando Vila
- Urology Department, Centro Hospitalar Tâmega e Sousa, 4564-007 Penafiel, Portugal; (F.V.); (J.L.)
| | - Rui Versos
- Urology Department, Hospital da Senhora da Oliveira—Guimarães, 4835-044 Guimarães, Portugal; (R.V.); (R.R.)
| | - Bernardo Lobão Teixeira
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Maria Alexandra Rocha
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Sofia Mesquita
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Miguel Marques-Monteiro
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Paulo Príncipe
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Ricardo Ramires
- Urology Department, Hospital da Senhora da Oliveira—Guimarães, 4835-044 Guimarães, Portugal; (R.V.); (R.R.)
| | - Joaquim Lindoro
- Urology Department, Centro Hospitalar Tâmega e Sousa, 4564-007 Penafiel, Portugal; (F.V.); (J.L.)
| | - Avelino Fraga
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| | - Miguel Silva-Ramos
- Urology Department, Centro Hospitalar Universitário de Santo António, 4099-001 Porto, Portugal; (G.M.); (M.M.); (B.L.T.); (M.A.R.); (S.M.); (M.M.-M.); (P.P.); (A.F.)
| |
Collapse
|
4
|
Calpin GG, Ryan FR, McHugh FT, McGuire BB. Comparing the outcomes of open, laparoscopic and robot-assisted partial nephrectomy: a network meta-analysis. BJU Int 2023; 132:353-364. [PMID: 37259476 DOI: 10.1111/bju.16093] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
OBJECTIVE To perform a systematic review and network meta-analysis (NMA) to determine the advantages and disadvantages of open (OPN), laparoscopic (LPN), and robot-assisted partial nephrectomy (RAPN) with particular attention to intraoperative, immediate postoperative, as well as longer-term functional and oncological outcomes. METHODS A systematic review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-NMA guidelines. Binary data were compared using odds ratios (ORs). Mean differences (MDs) were used for continuous variables. ORs and MDs were extracted from the articles to compare the efficacy of the various surgical approaches. Statistical validity is guaranteed when the 95% credible interval does not include 1. RESULTS In total, there were 31 studies included in the NMA with a combined 7869 patients. Of these, 33.7% (2651/7869) underwent OPN, 20.8% (1636/7869) LPN, and 45.5% (3582/7689) RAPN. There was no difference for either LPN or RAPN as compared to OPN in ischaemia time, intraoperative complications, positive surgical margins, operative time or trifecta rate. The estimated blood loss (EBL), postoperative complications and length of stay were all significantly reduced in RAPN when compared with OPN. The outcomes of RAPN and LPN were largely similar except the significantly reduced EBL in RAPN. CONCLUSION This systematic review and NMA suggests that RAPN is the preferable operative approach for patients undergoing surgery for lower-staged RCC.
Collapse
Affiliation(s)
- Gavin G Calpin
- Department of Urology, St. Vincent's University Hospital, Dublin 4, Ireland
| | - Fintan R Ryan
- Department of Urology, St. Vincent's University Hospital, Dublin 4, Ireland
| | | | - Barry B McGuire
- Department of Urology, St. Vincent's University Hospital, Dublin 4, Ireland
| |
Collapse
|
5
|
Fallara G, Larcher A, Dabestani S, Fossati N, Järvinen P, Nisen H, Gudmundsson E, Lam TB, Marconi L, Fernandéz-Pello S, Meijer RP, Volpe A, Beisland C, Klatte T, Stewart GD, Bensalah K, Ljungberg B, Bertini R, Montorsi F, Bex A, Capitanio U. Recurrence pattern in localized RCC: results from a European multicenter database (RECUR). Urol Oncol 2022; 40:494.e11-494.e17. [DOI: 10.1016/j.urolonc.2022.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Revised: 06/08/2022] [Accepted: 08/18/2022] [Indexed: 10/14/2022]
|
6
|
Zhang XM, Xu JD, Lv JM, Pan XW, Cao JW, Chu J, Cui XG. “Zero ischemia” laparoscopic partial nephrectomy by high-power GreenLight laser enucleation for renal carcinoma: A single-center experience. World J Clin Cases 2022; 10:5646-5654. [PMID: 35979100 PMCID: PMC9258349 DOI: 10.12998/wjcc.v10.i17.5646] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Revised: 03/16/2022] [Accepted: 04/09/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Laparoscopic partial nephrectomy has been widely used in renal cell carcinoma treatment. The efficacy of GreenLight laser on Laparoscopic partial nephrectomy is still unknown.
AIM To present the first series of laparoscopic partial nephrectomy (LPN) by GreenLight laser enucleation without renal artery clamping. Due to the excellent coagulation and hemostatic properties of the laser, laser-assisted LPN (LLPN) makes it possible to perform a “zero ischemia” resection.
METHODS Fifteen patients with T1a exogenous renal tumors who received high-power GreenLight laser non-ischemic LPN in our hospital were retrospectively analyzed. All clinical information, surgical and post-operative data, complications, pathological and functional outcomes were analyzed.
RESULTS Surgery was successfully completed in all patients, and no open or radical nephrectomy was performed. The renal artery was not clamped, leading to no ischemic time. No blood transfusions were required, the average hemoglobin level ranged from 96.0 to 132.0 g/L and no postoperative complications occurred. The mean operation time was 104.3 ± 8.2 min. The postoperative removal of negative pressure drainage time ranged from 5.0 to 7.0 d, and the mean postoperative hospital stay was 6.5 ± 0.7 d. No serious complications occurred. Postoperative pathological results showed clear cell carcinoma in 12 patients, papillary renal cell carcinoma in 2 patients, and hamartoma in 1 patient. The mean creatinine level was 75.0 ± 0.8 μmol/L (range 61.0-90.4 μmol/L) at 1 mo after surgery, and there were no statistically significant differences compared with pre-operation (P > 0.05). The glomerular filtration rate ranged from 45.1 to 60.8 mL/min, with an average of 54.0 ± 5.0 mL/min, and these levels were not significantly different from those before surgery (P > 0.05).
CONCLUSION GreenLight laser has extraordinary cutting and sealing advantages when used for small renal tumors (exogenous tumors of stage T1a) during LPN. However, use of this technique can lead to the generation of excessive smoke.
Collapse
Affiliation(s)
- Xiang-Min Zhang
- Department of Urology, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200092, China
- Department of Urology, Shanghai Baoshan Luodian Hospital, Shanghai 201908, China
| | - Ji-Dong Xu
- Department of Urology, Gongli Hospital of The Second Military Medical University, Shanghai 200135, China
| | - Jian-Min Lv
- Department of Urology, Shanghai The Seventh People's Hospital, Shanghai 200137, China
| | - Xiu-Wu Pan
- Department of Urology, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200092, China
| | - Jian-Wei Cao
- Department of Urology, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200092, China
| | - Jian Chu
- Department of Urology, Shanghai Baoshan Luodian Hospital, Shanghai 201908, China
| | - Xin-Gang Cui
- Department of Urology, Xinhua Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200092, China
| |
Collapse
|
7
|
Role and Utility of Mixed Reality Technology in Laparoscopic Partial Nephrectomy: Outcomes of a Prospective RCT Using an Indigenously Developed Software. Adv Urol 2022; 2022:8992051. [PMID: 35615077 PMCID: PMC9126718 DOI: 10.1155/2022/8992051] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 04/07/2022] [Accepted: 04/23/2022] [Indexed: 11/17/2022] Open
Abstract
Objective To develop a software for mixed reality (MR) anatomical model creation and study its intraoperative clinical utility to facilitate laparoscopic partial nephrectomy. Materials and Methods After institutional review board approval, 47 patients were prospectively randomized for LPN into two groups: the control group (24 patients) underwent operation with an intraoperative ultrasound (US) control and the experimental group (23 patients) with smart glasses HoloLens 2 (Microsoft, Seattle, WA, USA). Our team has developed an open-source software package called “HLOIA,” utilization of which allowed to create and use during surgery the MR anatomical model of the kidney with its vascular pedicle and tumor. The study period extended from June 2020 to February 2021 where demographic, perioperative, and pathological data were collected for all qualifying patients. The objective was to assess the utility of a MR model during LPN and through a 5-point Likert scale questionnaire, completed by the surgeon, immediately after LPN. Patient characteristics were tested using the chi-square test for categorical variables and Student's t-test or Mann–Whitney test for continuous variables. Results Comparison of the variables between the groups revealed statistically significant differences only in the following parameters: the time for renal pedicle exposure and the time from the renal pedicle to the detection of tumor localization (p < 0.001), which were in favor of the experimental group. The surgeon's impression of the utility of the MR model by the proposed questionnaire demonstrated high scores in all statements. Conclusions Developed open-source software “HLOIA” allowed to create the mixed reality anatomical model by operating urologist which is when used with smart glasses has shown improvement in terms of time for renal pedicle exposure and time for renal tumor identification without compromising safety.
Collapse
|
8
|
Diagnosis and Treatment of Small Renal Masses: Where Do We Stand? Curr Urol Rep 2022; 23:99-111. [PMID: 35507213 DOI: 10.1007/s11934-022-01093-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/03/2022] [Indexed: 01/20/2023]
Abstract
PURPOSE OF REVIEW To present an overview of the current evidence-based studies covering diagnostic and management of SRM. RECENT FINDINGS Renal cell carcinoma (RCC) represents 3% of the cancers. Nowadays, partial nephrectomy (PN) represents gold standard treatment. New nephron-sparing approaches such as active surveillance and ablative therapies have been increasingly used as an alternative to surgical intervention. Due to novel comprehension of RCC and widespread use of imaging techniques, diagnosis at early stage in elderly patients has increased. Treatment decision-making should be based on patient and tumour characteristics. With expanding treatment options, the management of SRMs has become a debate and should be adjusted to patient and tumour characteristics. In a shared decision manner, both active surveillance with possible delayed intervention and focal therapy should be discussed with the patient as an alternative to partial nephrectomy.
Collapse
|
9
|
Henderickx MMEL, Baldew SV, Marconi L, van Dijk MD, van Etten-Jamaludin FS, Lagerveld BW, Bex A, Zondervan PJ. Surgical margins after partial nephrectomy as prognostic factor for the risk of local recurrence in pT1 RCC: a systematic review and narrative synthesis. World J Urol 2022; 40:2169-2179. [PMID: 35503118 PMCID: PMC9427912 DOI: 10.1007/s00345-022-04016-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 04/08/2022] [Indexed: 11/28/2022] Open
Abstract
Purpose To systematically review the published literature on surgical margins as a risk factor for local recurrence (LR) in patients undergoing partial nephrectomy (PN) for pT1 renal cell carcinomas (RCC). Evidence acquisition A systematic literature search of relevant databases (MEDLINE, Embase and the Cochrane Library) was performed according to the PRISMA criteria up to February 2022. The hypothesis was developed using the PPO method (Patients = patients with pT1 RCC undergoing PN, Prognostic factor = positive surgical margins (PSM) detected on final pathology versus negative surgical margins (NSM) and Outcome = LR diagnosed on follow-up imaging). The primary outcome was the rate of PSM and LR. The risk of bias was assessed by the QUIPS tool. Evidence synthesis After assessing 1525 abstracts and 409 full-text articles, eight studies met the inclusion criteria. The percentage of PSM ranged between 0 and 34.3%. In these patients with PSM, LR varied between 0 and 9.1%, whereas only 0–1.5% of LR were found in the NSM-group. The calculated odds ratio (95% confident intervals) varied between 0.04 [0.00–0.79] and 0.27 [0.01–4.76] and was statistically significant in two studies (0.14 [0.02–0.80] and 0.04 [0.00–0.79]). The quality analysis of the included studies resulted in an overall intermediate to high risk of bias and the level of evidence was overall very low. A meta-analysis was considered unsuitable due to the high heterogeneity between the included studies. Conclusion PSM after PN in patients with pT1 RCC is associated with a higher risk of LR. However, the evidence has significant limitations and caution should be taken with the interpretation of this data. Supplementary Information The online version contains supplementary material available at 10.1007/s00345-022-04016-0.
Collapse
Affiliation(s)
- Michaël M. E. L. Henderickx
- Department of Urology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Suraj V. Baldew
- Department of Urology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | - Lorenzo Marconi
- Department of Urology, Coimbra University Hospital, Coimbra, Portugal
| | - Marcel D. van Dijk
- Faculty of Medicine (AMC), University of Amsterdam, Amsterdam, The Netherlands
| | - Faridi S. van Etten-Jamaludin
- Research Support, Medical Library, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| | | | - Axel Bex
- The Royal Free London NHS Foundation Trust and UCL Division of Surgery and Interventional Science, London, UK
- Department of Urology, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Patricia J. Zondervan
- Department of Urology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| |
Collapse
|
10
|
Liu Z, Zhang X, Lv P, Wu B, Bai S. Functional, oncological outcomes and safety of laparoscopic partial nephrectomy versus open partial nephrectomy in localized renal cell carcinoma patients with high anatomical complexity. Surg Endosc 2022; 36:7629-7637. [PMID: 35411462 DOI: 10.1007/s00464-022-09225-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 03/26/2022] [Indexed: 12/24/2022]
Abstract
PURPOSE Partial nephrectomy (PN) is the main treatment strategy for localized renal cell carcinoma (RCC). However, for RCC with high anatomical complexity, PN remains a challenge for urologists. Therefore, this study aimed to evaluate the functional oncological outcomes and safety of laparoscopic partial nephrectomy (LPN) versus open partial nephrectomy (OPN) in localized RCC patients with highly anatomical complexity (R.E.N.A.L. score ≥ 10). PATIENTS AND METHODS We retrospectively studied 575 patients who underwent PN at our center between January 2007 and December 2017. After propensity score-matching (PSM), 137 patients treated with LPN and 54 patients treated with OPN were balanced into 97 and 44 pairs. Patient demographics, and extensive perioperative and prognostic data were recorded and compared. RESULTS In the matched group, the OPN group had significantly less eGFR loss than the LPN group (2.57 ml/min/1.73 m2 vs. 31.59 ml/min/1.73 m2, P < 0.001). The recurrence-free survival (P = 0.287), overall survival (P = 0.296), cancer-specific survival (P = 0.664), and cardiocerebrovascular disease-specific survival (P = 0.341) were equivalent between groups. The rates of minor (P = 0.621) and major (P = 0.647) complications were also similar between groups. CONCLUSIONS This PSM cohort study showed that OPN resulted in better renal function preservation than LPN in localized RCC patients with high anatomical complexity, and had comparable oncological and safety outcomes after long-term follow-up. These findings may help improve clinical decision-making for localized RCC patients with high anatomical complexity.
Collapse
Affiliation(s)
- Zeqi Liu
- Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China
| | - Xuanyu Zhang
- Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China
| | - Peng Lv
- Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China
| | - Bin Wu
- Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China
| | - Song Bai
- Department of Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, Liaoning, 110004, People's Republic of China.
| |
Collapse
|
11
|
Kanda S, Inoue T, Nakajima S, Sagehashi R, Nara T, Numakura K, Saito M, Narita S, Tsuchiya N, Habuchi T. Comparison of parenchymal volume loss assessed by three-dimensional computed tomography volumetry and renal functional recovery between conventional and robot-assisted laparoscopic partial nephrectomy. Asian J Endosc Surg 2022; 15:63-69. [PMID: 34227254 DOI: 10.1111/ases.12966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 06/19/2021] [Accepted: 06/23/2021] [Indexed: 11/27/2022]
Abstract
OBJECTIVES We retrospectively investigated if robot-assisted laparoscopic partial nephrectomy (RAPN) contributes to a decrease in resected parenchymal volume (RPV), an increase in postoperative parenchymal volume (PPV), and an improvement of postoperative renal function when compared with conventional laparoscopic partial nephrectomy (LPN) using a three-dimensional image analysis system. METHODS Patients who underwent LPN (n = 37) and RAPN (n = 66) from November 2013 to November 2018 were included in this study. All patients had a tumor diameter of 4 cm or less. Patients with an anatomical or functional single kidney were excluded. RPV and PPV were measured using SYNAPSE VINCENT®. The surgical outcomes were compared between the two groups. RESULTS Warm ischemic time in the RAPN group was significantly shorter than that in the LPN group (p < 0.001). The ratio of RPV to tumor volume (RPV/TV) in the RAPN group was significantly lower than that in the LPN group (p = 0.016). PPV in the RAPN group was significantly higher than that in the LPN group (p = 0.049). The decreased estimated glomerular filtration rate in the RAPN group was significantly lower than that in the LPN group on days 1, 7, 30, 90, and 180 after surgery. CONCLUSIONS Postoperative renal function in the RAPN group was significantly better than that in the LPN group in both the short and long term. In addition to a short warm ischemia time, the decreased RPV/TV and increased PPV may have contributed to the improvement of postoperative renal function.
Collapse
Affiliation(s)
- Sohei Kanda
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.,Department of Urology, Akita Red Cross Hospital, Akita, Japan
| | - Takamitsu Inoue
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.,Department of Renal and Urological Surgery, International University of Health and Welfare Narita Hospital, Chiba, Japan
| | - Shiori Nakajima
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Ryuichiro Sagehashi
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Taketoshi Nara
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Kazuyuki Numakura
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Mitsuru Saito
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Shintaro Narita
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Norihiko Tsuchiya
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| | - Tomonori Habuchi
- Department of Urology, Akita University Graduate School of Medicine, Akita, Japan
| |
Collapse
|
12
|
Shao Z, Tan S, Yu X, Liu H, Jiang Y, Gao J. Laparoscopic nephron-sparing surgery for a tumor near the isthmus of a horseshoe kidney with a complicated blood supply. J Int Med Res 2021; 48:300060520926736. [PMID: 32489122 PMCID: PMC7273767 DOI: 10.1177/0300060520926736] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
A horseshoe kidney is a congenital kidney malformation commonly associated with
complications such as hydronephrosis, renal calculi, and infections of the renal pelvis.
Renal cell carcinoma is extremely rare in a horseshoe kidney; once it occurs, however, it
is intractable because of vascular abnormalities. This is especially true in laparoscopic
nephron-sparing surgery, even for tumors of <4 cm in diameter. We herein report a case
involving an asymptomatic 65-year-old man with an incidental finding of a 4-cm solid mass
near the isthmus of a horseshoe kidney on B-mode ultrasonography. Preoperative computed
tomography of the renal artery revealed six arterial vessels supplying the affected
kidney. Laparoscopic partial nephrectomy was performed. The outcome of this case suggests
that laparoscopic nephron-sparing surgery might be a successful treatment method for a
horseshoe kidney but that preoperative vessel evaluation and experienced laparoscopic
skills are needed.
Collapse
Affiliation(s)
- Zhiqiang Shao
- Department of Urology, the Linyi People's Hospital, Linyi, Shandong province, China
| | - Shanfeng Tan
- Department of Urology, the Linyi People's Hospital, Linyi, Shandong province, China
| | - Xiaohong Yu
- Department of Urology, the Linyi People's Hospital, Linyi, Shandong province, China
| | - Hongjun Liu
- Department of Urology, the Third Linyi People's Hospital, Linyi, Shandong province, China
| | - Yongjun Jiang
- Department of Urology, the Third Linyi People's Hospital, Linyi, Shandong province, China
| | - Jiangping Gao
- Department of Urology, the Fourth Medical Center of PLA General Hospital, Beijing, China
| |
Collapse
|
13
|
Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy. Surg Endosc 2021; 36:663-669. [PMID: 33591449 PMCID: PMC8741715 DOI: 10.1007/s00464-021-08333-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2020] [Accepted: 01/13/2021] [Indexed: 01/22/2023]
Abstract
BACKGROUND Improvements in laparoscopic partial nephrectomy (LPN) in order to minimize perioperative warm ischemia time (WIT), complications, and consequently patient outcome are desirable. Veriset™ is a ready-to-use hemostatic patch of absorbable oxidized cellulose and hydrogel components that has earlier been implemented in vascular and hepatic surgery. We report our experience using this device in LPN. METHODS Patients with a solitary malignant renal mass suspicious for renal cancer underwent LPN with either the use of Veriset™ hemostatic patch (n = 40) or conventional suture technique (n = 40). Patient characteristics, operation time and WIT, postoperative course and complications were recorded retrospectively. Tumor complexity was calculated according to the R.E.N.A.L. score. Outcome was determined according to the "trifecta" criteria (negative surgical margin, WIT < 25 min, no complications within 30 days). RESULTS No significant differences with regard to clinical parameters and median R.E.N.A.L. score (6) were observed between both groups. Operation time (mean 127.1 min vs. 162. 8 min; p = 0.001) and WIT were both lower in the Veriset™ group (14.6 min vs. 20.6 min; p = 0.01). No differences in surgical margins (p = 0.602) and overall complication rates at 30 (p = 0.599) and 90 days (p = 0.611) postoperatively were noticed. The surgical outcome according to "trifecta" was achieved in 65% of patients using Veriset™ and in 57.5% of patients by suture closure, respectively. CONCLUSION The hemostatic Veriset™ patch can successfully be implemented in LPN. Handling and application appear favorable, thereby reducing operation time and WIT. The present results suggest that the device may represent an alternative to parenchyma suturing in LPN.
Collapse
|
14
|
You C, Du Y, Wang H, Peng L, Wei T, Zhang X, Li X, Wang A. Laparoscopic Versus Open Partial Nephrectomy: A Systemic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes. Front Oncol 2020; 10:583979. [PMID: 33194725 PMCID: PMC7658533 DOI: 10.3389/fonc.2020.583979] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 09/24/2020] [Indexed: 12/25/2022] Open
Abstract
Purpose To summarize and analyze the current evidence about surgical, oncological, and functional outcomes between laparoscopic partial nephrectomy (LPN) and open partial nephrectomy (OPN). Materials and Methods Through a systematical search of multiple scientific databases in March 2020, we performed a systematic review and cumulative meta-analysis. Meanwhile, we assessed the quality of the relevant evidence according to the framework in the Cochrane Handbook for Systematic Reviews of Interventions. Results A total of 26 studies with 8095 patients were included. There was no statistical difference between the LPN and OPN in the terms of operation time (p=0.13), intraoperative complications (p=0.94), recurrence (p=0.56), cancer-specific survival (p=0.72), disease-free survival (p=0.72), and variations of estimated glomerular filtration rate (p=0.31). The LPN group had significantly less estimated blood loss (P<0.00001), lower blood transfusion (p=0.04), shorter length of hospital stay (p<0.00001), lower total (p=0.03) and postoperative complications (p=0.02), higher positive surgical margin (p=0.005), higher overall survival (p<0.00001), and less increased serum creatinine (p=0.002). The subgroup analysis showed that no clinically meaningful differences were found for T1a tumors in terms of operation time (p=0.11) and positive surgical margin (p=0.23). In addition, the subgroup analysis also suggested that less estimated blood loss (p<0.0001) and shorter length of hospital stay (p<0.00001) were associated with the LPN group for T1a tumors. Conclusions This meta-analysis revealed that the LPN is a feasible and safe alternative to the OPN with comparable surgical, oncologic, and functional outcomes. However, the results should be applied prudently in the clinic because of the low quality of evidence. Further quality studies are needed to evaluate the effectiveness LPN and its postoperative quality of life compared with OPN.
Collapse
Affiliation(s)
- Chengyu You
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| | - Yuelin Du
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| | - Hui Wang
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| | - Lei Peng
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| | - Tangqiang Wei
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| | - Xiaojun Zhang
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| | - Xianhui Li
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| | - Anguo Wang
- Department of Urology, Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College (University), Nanchong, China
| |
Collapse
|
15
|
Ohtake S, Makiyama K, Yamashita D, Tatenuma T, Yamanaka H, Yao M. Validation of a kidney model made of N-composite gel as a training tool for laparoscopic partial nephrectomy. Int J Urol 2020; 27:567-568. [PMID: 32253774 DOI: 10.1111/iju.14240] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Shinji Ohtake
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Kazuhide Makiyama
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Daisuke Yamashita
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.,Department of Urology, Yokohama Sakae Kyosai Hospital, Yokohama, Japan
| | - Tomoyuki Tatenuma
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Hiroyuki Yamanaka
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Masahiro Yao
- Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| |
Collapse
|
16
|
Khalil MI, Ubeda J, Soehner T, Bhandari NR, Payakachat N, Davis R, Raheem OA, Kamel MH. Contemporary Perioperative Morbidity and Mortality Rates of Minimally Invasive vs Open Partial Nephrectomy in Obese Patients with Kidney Cancer. J Endourol 2019; 33:920-927. [PMID: 31333072 DOI: 10.1089/end.2019.0310] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Aims: To compare early postoperative morbidity and mortality rates in obese patients (body mass index ≥30 kg/m2) who underwent minimally invasive partial nephrectomy (MIPN) vs open partial nephrectomy (OPN), utilizing the National Surgical Quality Improvement Program (NSQIP) database. Materials and Methods: The NSQIP database was queried to identify obese patients who underwent either MIPN or OPN between 2008 and 2016. Patient demographics, comorbidities, operative time (OT), length of stay (LOS), and 30-day postoperative complications, readmissions, and mortality rates were recorded and compared between the two groups. Multivariable logistic regression analysis was used to determine the adjusted odds of early postoperative complications in MIPN vs OPN. Results: A total of 6041 obese MIPN patients and 3064 obese OPN patients were identified. Mean OT (minutes ± standard deviation) was longer for MIPN vs OPN (197.2 ± 71.0 vs 189.6 ± 82.4, p < 0.001), while mean LOS (3.8 ± 2.8 days vs 5.8 ± 3.5 days, p < 0.001) and 30-day complications (8.5% vs 19.8%, p < 0.001) were lower. No difference in 30-day postoperative mortality rates between MIPN (0.4%) and OPN (0.5%) was observed (p = 0.426). In the adjusted analysis, the odds of any complication within 30 days in the MIPN group were 61% lower, blood transfusion 73% lower, pneumonia 38% lower, sepsis 70% lower, acute renal failure 64% lower, superficial surgical site infection 40% lower, and reoperation 47% lower, compared with OPN patients. Conclusions: When compared with OPN in obese patients, the likelihood of 30-day postoperative morbidity was significantly lower in MIPN patients. However, the odds of 30-day mortality rates were similar between the groups.
Collapse
Affiliation(s)
- Mahmoud I Khalil
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.,Department of Urology, Ain Shams University, Cairo, Egypt
| | - Joel Ubeda
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Thomas Soehner
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Naleen Raj Bhandari
- Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Nalin Payakachat
- Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Rodney Davis
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Omer A Raheem
- Department of Urology, Tulane University, New Orleans, Louisiana
| | - Mohamed H Kamel
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.,Department of Urology, Ain Shams University, Cairo, Egypt
| |
Collapse
|
17
|
Surgical Methods in Treatment of Kidney Tumors: Open Surgery Versus Laparoscopy Versus Robotic Surgery. Urol Oncol 2019. [DOI: 10.1007/978-3-319-42623-5_63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Drerup M, Magdy A, Hager M, Colleselli D, Kunit T, Lusuardi L, Janetschek G, Mitterberger M. Non-ischemic laparoscopic partial nephrectomy using 1318-nm diode laser for small exophytic renal tumors. BMC Urol 2018; 18:99. [PMID: 30413201 PMCID: PMC6230292 DOI: 10.1186/s12894-018-0405-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2018] [Accepted: 10/16/2018] [Indexed: 12/13/2022] Open
Abstract
Purpose Warm ischemia (WI) and bleeding constitute the main challenges for surgeons during laparoscopic partial nephrectomy (LPN). Current literature on the use of lasers for cutting and coagulation remains scarce and with small cohorts. We present the largest case series to date of non-ischemic LPN using a diode laser for small exophytic renal tumors. Methods We retrospectively evaluated 29 patients with clinically localized exophytic renal tumors who underwent non-ischemic laser–assisted LPN with a 1318-nm wavelength diode laser. We started applying the laser 5 mm beyond the visible tumor margin, 5 mm away from the tissue in a non-contact fashion for coagulation and in direct contact with the parenchymal tissue for cutting. Results The renal vessels were not clamped, resulting in a WIT (warm ischaemic time) of 0 min, except for one case that required warm ischemia for 12 min and parenchymal sutures. No transfusion was needed, with a mean Hemoglobin drop of 1,4 mg/dl and no postoperative complications. The eGFR did not significantly change by 6 months. Histologically, the majority of lesions (n = 22/29) were renal-cell carcinoma stage pT1a. The majority of malignant lesions (n = 13/22) had a negative margin. However, margin interpretation was difficult in 9 cases due to charring of the tumor base. A mean follow-up of 1.8 years revealed no tumor recurrence. The mean tumor diameter was 19.4 mm. Conclusion The 1318-nm diode laser has the advantages of excellent cutting and sealing properties when applied to small vessels in the renal parenchyma, reducing the need for parenchymal sutures. However, excessive smoke, charring of the surgical margin, and inability to seal large blood vessels are encountered with this technique.
Collapse
Affiliation(s)
- Martin Drerup
- Department of Urology, Paracelsus Medical University Salzburg, Muellner-Hauptstrasse 48, 5020, Salzburg, Austria
| | - Ahmed Magdy
- Department of Urology, Paracelsus Medical University Salzburg, Muellner-Hauptstrasse 48, 5020, Salzburg, Austria
| | - Martina Hager
- Department of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria.
| | - Daniela Colleselli
- Department of Urology, Paracelsus Medical University Salzburg, Muellner-Hauptstrasse 48, 5020, Salzburg, Austria
| | - Thomas Kunit
- Department of Urology, Paracelsus Medical University Salzburg, Muellner-Hauptstrasse 48, 5020, Salzburg, Austria
| | - Lukas Lusuardi
- Department of Urology, Paracelsus Medical University Salzburg, Muellner-Hauptstrasse 48, 5020, Salzburg, Austria
| | - Günter Janetschek
- Department of Urology, Paracelsus Medical University Salzburg, Muellner-Hauptstrasse 48, 5020, Salzburg, Austria
| | - Michael Mitterberger
- Department of Urology, Paracelsus Medical University Salzburg, Muellner-Hauptstrasse 48, 5020, Salzburg, Austria
| |
Collapse
|
19
|
Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A. Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du rein. Prog Urol 2018; 28 Suppl 1:R5-R33. [DOI: 10.1016/j.purol.2019.01.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 09/15/2018] [Indexed: 12/15/2022]
|
20
|
Sperling CD, Xia L, Berger IB, Shin MH, Strother MC, Guzzo TJ. Obesity and 30-Day Outcomes Following Minimally Invasive Nephrectomy. Urology 2018; 121:104-111. [DOI: 10.1016/j.urology.2018.08.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2018] [Revised: 07/23/2018] [Accepted: 08/01/2018] [Indexed: 12/23/2022]
|
21
|
Bensalah K, Albiges L, Bernhard JC, Bigot P, Bodin T, Boissier R, Correas JM, Gimel P, Hetet JF, Long JA, Nouhaud FX, Ouzaïd I, Rioux-Leclercq N, Méjean A. RETRACTED: Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : prise en charge du cancer du reinFrench ccAFU guidelines – Update 2018–2020: Management of kidney cancer. Prog Urol 2018; 28:S3-S31. [PMID: 30473002 DOI: 10.1016/j.purol.2018.09.009] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 09/15/2018] [Indexed: 12/15/2022]
Abstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).
Cet article est retiré de la publication à la demande des auteurs car ils ont apporté des modifications significatives sur des points scientifiques après la publication de la première version des recommandations.
Le nouvel article est disponible à cette adresse: DOI:10.1016/j.purol.2019.01.004.
C’est cette nouvelle version qui doit être utilisée pour citer l’article.
This article has been retracted at the request of the authors, as it is not based on the definitive version of the text because some scientific data has been corrected since the first issue was published.
The replacement has been published at the DOI:10.1016/j.purol.2019.01.004.
That newer version of the text should be used when citing the article.
Collapse
Affiliation(s)
- K Bensalah
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital Pontchaillou, CHU de Rennes, 2, rue Henri-Le-Guilloux, 35033, Rennes cedex, France.
| | - L Albiges
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Département d'oncologie génito-urinaire, Gustave-Roussy, 94805, Villejuif cedex, France
| | - J-C Bernhard
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie et transplantation rénale, CHU de Bordeaux, place Amélie-Raba-Léon, 33076, Bordeaux, France
| | - P Bigot
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, CHU d'Angers, 4, rue Larrey, 49000, Angers, France
| | - T Bodin
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Centre d'urologie Prado-Louvain, 188, rue du Rouet, 13008, Marseille, France
| | - R Boissier
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie et transplantation rénale, CHU Conception, 147, boulevard Baille, 13005, Marseille, France
| | - J-M Correas
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'imagerie médicale (radiologie), hôpital universitaire Necker-Enfants-malades, 149, rue de Sèvres, 75015, Paris, France
| | - P Gimel
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Centre d'urologie, site Médipôle, 5, avenue Ambroise-Croizat, 66330, Cabestany, France
| | - J-F Hetet
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service de chirurgie urologique, clinique Jules-Verne, 2-4, route de Paris, 44314, Nantes, France
| | - J-A Long
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service de chirurgie urologique et de la transplantation rénale, hôpital Michallon, CHU Grenoble, boulevard de la Chantourne, 38700, La Tronche, France
| | - F-X Nouhaud
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, CHU de Rouen, 1, rue de Germont, 76000, Rouen, France
| | - I Ouzaïd
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Clinique urologique, hôpital Bichat-Claude-Bernard, 46, rue Henri-Huchard, 75018, Paris, France
| | - N Rioux-Leclercq
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'anatomie et cytologie pathologiques, CHU Pontchaillou, 2, rue Henri-le-Guilloux, 35033, Rennes cedex 9, France
| | - A Méjean
- Comité de cancérologie de l'Association française d'urologie, groupe rein, maison de l'urologie, 11, rue Viète, 75017, Paris, France; Service d'urologie, hôpital européen Georges-Pompidou, université Paris Descartes, AP-HP, 75015, Paris, France
| |
Collapse
|
22
|
Alsharm A, Bazarbashi S, Alghamdi A, Alkhateeb S, Aljubran A, Abusamra A, Alharbi H, Alotaibi M, Almansour M, Alkushi H, Ahmed I, Murshid E, Eltijani A, Rabah D. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017. Urol Ann 2018; 10:123-132. [PMID: 29719321 PMCID: PMC5907318 DOI: 10.4103/ua.ua_175_17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
In this report, we update the previously published Saudi guidelines for the evaluation and medical and surgical management of renal cell carcinoma. It is categorized according to the stage of the disease using the tumor node metastasis staging system 7th edition. The recommendations are presented with supporting evidence level.
Collapse
Affiliation(s)
- Abdullah Alsharm
- Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Shouki Bazarbashi
- Oncology Center, Section of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Abdullah Alghamdi
- Department of Urology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Sultan Alkhateeb
- Department of Surgery, Division of Urology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Ali Aljubran
- Oncology Center, Section of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Ashraf Abusamra
- Department of Surgery, Urology Section, King Khalid Hospital, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Hulayel Alharbi
- Department of Medical Oncology, King Fahed Specialist Hospital, Dammam, Saudi Arabia
| | - Mohammed Alotaibi
- Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mubarak Almansour
- Department of Oncology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Hussein Alkushi
- Department of Pathology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Imran Ahmed
- Department of Oncology, Section of Medical Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
| | - Esam Murshid
- Department of Oncology, Oncology Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Amin Eltijani
- Department of Oncology, Division of Medical Oncology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Danny Rabah
- Department of Surgery, College of Medicine and Uro-Oncology Research Chair, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
23
|
Alsharm A, Bazarbashi S, Alghamdi A, Alkhateeb S, Aljubran A, Abusamra A, Alharbi H, Alotaibi M, Almansour M, Alkushi H, Ahmed I, Murshid E, Eltijani A, Rabah D. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017. Urol Ann 2018; 10:123-132. [PMID: 29719321 DOI: 10.4103/ua.ua-175-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
In this report, we update the previously published Saudi guidelines for the evaluation and medical and surgical management of renal cell carcinoma. It is categorized according to the stage of the disease using the tumor node metastasis staging system 7th edition. The recommendations are presented with supporting evidence level.
Collapse
Affiliation(s)
- Abdullah Alsharm
- Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Shouki Bazarbashi
- Oncology Center, Section of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Abdullah Alghamdi
- Department of Urology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Sultan Alkhateeb
- Department of Surgery, Division of Urology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Ali Aljubran
- Oncology Center, Section of Medical Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Ashraf Abusamra
- Department of Surgery, Urology Section, King Khalid Hospital, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Hulayel Alharbi
- Department of Medical Oncology, King Fahed Specialist Hospital, Dammam, Saudi Arabia
| | - Mohammed Alotaibi
- Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mubarak Almansour
- Department of Oncology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Hussein Alkushi
- Department of Pathology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Imran Ahmed
- Department of Oncology, Section of Medical Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
| | - Esam Murshid
- Department of Oncology, Oncology Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Amin Eltijani
- Department of Oncology, Division of Medical Oncology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Danny Rabah
- Department of Surgery, College of Medicine and Uro-Oncology Research Chair, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
24
|
Glybochko PV, Rapoport LM, Alyaev YG, Sirota ES, Bezrukov EA, Fiev DN, Byadretdinov IS, Bukatov MD, Letunovskiy AV, Korolev DO. Multiple application of three-dimensional soft kidney models with localized kidney cancer: A pilot study. Urologia 2018; 85:99-105. [DOI: 10.1177/0391560317749405] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Aim: To evaluate the effectiveness of three-dimensional printing application in urology for localized renal cancer treatment using three-dimensional printed soft models. Materials and methods: The study included five patients with kidney tumors. The patients were treated in the Urology Clinic of I.M. Sechenov First Moscow State Medical University from February 2016 to June 2017. Personalized three-dimensional printed models based on computed tomographic images were created. Five surgeons took part in a survey in which the utility of computed tomographic images versus three-dimensional printed models for presurgical planning was compared. A laparoscopic partial nephrectomy training using the developed three-dimensional printed models was performed by the same surgeons in a surgical training box. Results: The patients underwent endoscopic surgery using laparoscopic access. The average time of surgery was 187 min. All the operations were performed with complete renal artery clamping. The average warm ischemia time was 19.5 min and the average blood loss was 170 mL. No conversions to open surgery or radical nephrectomy, and no postoperative complications and deaths were observed. All the surgical margins were negative. The tumors were morphologically identified as renal cell carcinoma in four cases and as oncocytoma in one case. Conclusion: The developed three-dimensional printed models allow one to evaluate the pathological anatomy of tumors more effectively. High similarity between three-dimensional models and native kidneys contribute to improvement of surgical skills necessary for partial nephrectomy. Training on the three-dimensional models also allows surgeons to facilitate selection of an optimal surgical tactics for each patient.
Collapse
Affiliation(s)
- Peter Vitalevich Glybochko
- Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | | | - Yuri Gennadevich Alyaev
- Department of Urology, Clinic of Urology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Eugene Sergeevich Sirota
- Department of Urology, Clinic of Urology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Eugene Alexeevich Bezrukov
- Department of Urology, Clinic of Urology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Dmitry Nikolaevich Fiev
- Research Institute of Uronephrology and Human Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | | | | | | | - Dmitry Olegovich Korolev
- Department of Urology, Clinic of Urology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| |
Collapse
|
25
|
Banapour P, Abdelsayed GA, Bider-Canfield Z, Elliott PA, Kilday PS, Chien GW. Nephrometry score matched robotic vs. laparoscopic vs. open partial nephrectomy. J Robot Surg 2018; 12:679-685. [DOI: 10.1007/s11701-018-0801-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Accepted: 03/12/2018] [Indexed: 01/20/2023]
|
26
|
Luk ACO, Pandian RMK, Heer R. Laparoscopic renal surgery is here to stay. Arab J Urol 2018; 16:314-320. [PMID: 30140467 PMCID: PMC6104665 DOI: 10.1016/j.aju.2018.01.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Accepted: 01/23/2018] [Indexed: 01/20/2023] Open
Abstract
Objectives To review the current literature comparing the outcomes of renal surgery via open, laparoscopic and robotic approaches. Materials and methods A comprehensive literature search was performed on PubMed, MEDLINE and Ovid, to look for studies comparing outcomes of renal surgery via open, laparoscopic, and robotic approaches. Results Limited good-quality evidence suggests that all three approaches result in largely comparable functional and oncological outcomes. Both laparoscopic and robotic approaches result in less blood loss, analgesia requirement, with a shorter hospital stay and recovery time, with similar complication rates when compared with the open approach. Robotic renal surgeries have not shown any significant clinical benefit over a laparoscopic approach, whilst the associated cost is significantly higher. Conclusion With the high cost and lack of overt clinical benefit of the robotic approach, laparoscopic renal surgery will likely continue to remain relevant in treating various urological pathologies.
Collapse
Key Words
- (L)(LESS-)DN, (laparoscopic) (laparoendoscopic single-site-) donor nephrectomy
- (L)(O)(RA)PN, (laparoscopic) (open) (robot-assisted) partial nephrectomy
- (L)(O)(RA)PY, (laparoscopic) (open) (robot-assisted) pyeloplasty
- (L)(O)(RA)RN, (laparoscopic) (open) (robot-assisted) radical nephrectomy
- BMI, body mass index
- Donor nephrectomy
- LOS, length of hospital stay
- Laparoscopic/open/robotic renal surgery
- NOTES, natural orifice transluminal endoscopic surgery
- PUJO, PUJ obstruction
- Partial nephrectomy
- Pyeloplasty
- RCT, randomised controlled trial
- Radical nephrectomy
- WIT, warm ischaemia time
- eGFR, estimated GFR
Collapse
Affiliation(s)
- Angus Chin On Luk
- Department of Urology, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK
| | | | - Rakesh Heer
- Department of Urology, Freeman Hospital, High Heaton, Newcastle upon Tyne, UK
| |
Collapse
|
27
|
Kaygisiz O, Çelen S, Vuruşkan BA, Vuruşkan H. Comparison of two different suture techniques in laparoscopic partial nephrectomy. Int Braz J Urol 2017; 43:863-870. [PMID: 28727369 PMCID: PMC5678517 DOI: 10.1590/s1677-5538.ibju.2016.0550] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Accepted: 01/24/2017] [Indexed: 01/20/2023] Open
Abstract
Objective: To comparatively evaluate the traditional interrupted knot-tying and running suture renorrhaphy with Monocryl® in laparoscopic partial nephrectomy (LPN). Materials and Methods: A retrospective analysis of 62 consecutive patients undergoing LPN using traditional interrupted knot-tying suture renorrhaphy (Group 1; n=31) or running suture technique renorrhaphy with 2-0 monofilament polyglecaprone (Monocryl®, Ethicon) (Group 2; n=31) from December 2011 to October 2015 at the University. All patients underwent LPN performed by an experienced laparoscopic surgeon. The demographic, perioperative and postoperative parameters were compared between the groups, and the effect of both suture techniques on the warm ischemic time (WIT) and trifecta were evaluated. Results: The running suture renorrhaphy with Monocryl® reduced WIT, estimated blood lost and length of hospitalization stay significantly without increasing postoperative complication rate during LPN in comparison with interrupted knot-tying suture. Conclusion: The renorrhaphy using the running suture with Monocryl® is an effective and safe technique with the advantage of shortening WIT even in more challenging and larger tumors during LPN.
Collapse
Affiliation(s)
- Onur Kaygisiz
- Department of Urology, Uludag University, Faculty of Medicine, Bursa, Turkey
| | - Sinan Çelen
- Afyon Sandikli Government Hospital, Afyon, Turkey
| | - Berna Aytac Vuruşkan
- Department of Surgical Pathology, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - Hakan Vuruşkan
- Department of Urology, Uludag University, Faculty of Medicine, Bursa, Turkey
| |
Collapse
|
28
|
Tsivian M, Tsivian E, Stanevsky Y, Bass R, Sidi AA, Tsivian A. Laparoscopic partial nephrectomy for tumors 7cm and above. Perioperative outcomes. Int Braz J Urol 2017; 43:857-862. [PMID: 28792194 PMCID: PMC5678516 DOI: 10.1590/s1677-5538.ibju.2016.0642] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2016] [Accepted: 05/29/2017] [Indexed: 01/31/2023] Open
Abstract
PURPOSE To assess and report the outcomes of laparoscopic partial nephrectomy )LPN) for T2 renal masses. MATERIALS AND METHODS Retrospective review of patients undergoing LPN for clinically localized renal masses ≥7cm between the years 2005-2016. Descriptive analyses were generated for demographics, lesion characteristics, perioperative variables (operative time, warm ischemia time (WIT), estimated blood loss (EBL), intra-operative and post-operative complications (IOC and POC) and pathologic variables (pathology, subtype and Fuhrman grade). RESULTS A total of 27 patients underwent LPN for a T2 renal mass at our institution between 2005 and early 2016 of which 19 were males. The mean age was 66 (52-72). All procedures were transperitoneal with 16 on the right and 11 on the left. Median operative time was 200 minutes (IQR 181-236) and median WIT 19 minutes (IQR 16-23). EBL was 125mL (IQR 75-175). One case was converted to laparoscopic radical nephrectomy due to suspected tumor thrombus in the renal vein. Surgical margins were positive in one renal tumor in a patient with multiple tumors. There was a total of 2 IOC (7.4%) and 3 POC (11%) classified as Clavien grade 3. CONCLUSIONS To our knowledge, this series is the first to describe the outcomes of LPN for cT2 renal masses. In our series, LPN for larger renal masses appears feasible with favorable perioperative outcomes. Additional data are needed to further explore the benefits of minimally invasive surgical approaches to larger renal masses.
Collapse
Affiliation(s)
- Matvey Tsivian
- Division of Urology and Department of Surgery, Duke University Medical Center Durham, NC
| | - Efrat Tsivian
- Division of Urology and Department of Surgery, Duke University Medical Center Durham, NC
| | - Yury Stanevsky
- Department of Urologic Surgery, The E. Wolfson Medical Center, Holon and Sackler School of Medicine Tel Aviv University, Tel Aviv, Israel
| | - Roman Bass
- Department of Urologic Surgery, The E. Wolfson Medical Center, Holon and Sackler School of Medicine Tel Aviv University, Tel Aviv, Israel
| | - A Ami Sidi
- Department of Urologic Surgery, The E. Wolfson Medical Center, Holon and Sackler School of Medicine Tel Aviv University, Tel Aviv, Israel
| | - Alexander Tsivian
- Department of Urologic Surgery, The E. Wolfson Medical Center, Holon and Sackler School of Medicine Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
29
|
Song E, Ma X, An R, Zhang P, Zhang X, Wang B, Shi T, Sun S. Retroperitoneal Laparoscopic Partial Nephrectomy for Tumors Larger than 7 cm in Renal Cell Carcinoma: Initial Experience of Single-Institution. J Laparoendosc Adv Surg Tech A 2017; 27:1127-1131. [PMID: 28304214 DOI: 10.1089/lap.2016.0668] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Affiliation(s)
- Erlin Song
- Department of Urinary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China
- Key Laboratory of Cardiovascular Medicine Research, Ministry of Education, Harbin Medical University, Harbin, P.R. China
| | - Xin Ma
- Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy/State Key Laboratory of Kidney Diseases, Beijing, P.R. China
| | - Ruihua An
- Department of Urinary Surgery, First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China
| | - Peng Zhang
- Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy/State Key Laboratory of Kidney Diseases, Beijing, P.R. China
| | - Xu Zhang
- Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy/State Key Laboratory of Kidney Diseases, Beijing, P.R. China
| | - Baojun Wang
- Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy/State Key Laboratory of Kidney Diseases, Beijing, P.R. China
| | - Taoping Shi
- Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy/State Key Laboratory of Kidney Diseases, Beijing, P.R. China
| | - Shengkun Sun
- Department of Urology, Chinese PLA General Hospital/Chinese PLA Medical Academy/State Key Laboratory of Kidney Diseases, Beijing, P.R. China
| |
Collapse
|
30
|
Abstract
BACKGROUND The rising incidence of renal cell carcinoma, its more frequent early detection (stage T1a) and the increasing prevalence of chronic renal failure with higher morbidity and shorter life expectancy underscore the need for multimodal focal nephron-sparing therapy. DISCUSSION During the past decade, the gold standard shifted from radical to partial nephrectomy. Depending on the surgeon's experience, the patient's constitution and the tumor's location, the intervention can be performed laparoscopically with the corresponding advantages of lower invasiveness. A treatment alternative can be advantageous for selected patients with high morbidity and/or an increased risk of complications associated with anesthesia or surgery. Corresponding risk stratification necessitates previous confirmation of the small renal mass (cT1a) by histological examination of biopsy samples. Active surveillance represents a controlled delay in the initiation of treatment. RESULTS Percutaneous radiofrequency ablation (RFA) and laparoscopic cryoablation are currently the most common treatment alternatives, although there are limitations particularly for renal tumors located centrally near the hilum. More recent ablation procedures such as high intensity focused ultrasound (HIFU), irreversible electroporation, microwave ablation, percutaneous stereotactic ablative radiotherapy and high-dose brachytherapy have high potential in some cases but are currently regarded as experimental for the treatment of renal cell carcinoma.
Collapse
|
31
|
The Application of Internal Suspension Technique in Retroperitoneal Laparoscopic Partial Nephrectomy for Renal Ventral Tumors. BIOMED RESEARCH INTERNATIONAL 2017. [PMID: 28630859 PMCID: PMC5467276 DOI: 10.1155/2017/1849649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objective To evaluate the feasibility of an internal suspension technique in retroperitoneal laparoscopic partial nephrectomy for the management of renal ventral tumors. Methods Between January 2013 and July 2016, a total of 145 patients underwent retroperitoneal laparoscopic partial nephrectomy with or without internal suspension technique. For patients who underwent internal suspension technique, the surgeons preserved the external fat of the renal tumor as a suspension traction measure when separating the kidney. Propensity score matching (PSM) was performed according to age, gender, body mass index, tumor size, tumor location, and RENAL nephrometry score. Patient characteristics and intraoperative and postoperative outcomes were compared between the groups. Results After PSM, 32 patients treated with the internal suspension technique were compared with 32 cases treated without such technique. Baseline characteristics were statistically similar for the cohorts. The use of our new technique resulted in shorter warm ischemia time (WIT: 15.0 versus 19.0 minutes, P = .002) and tumor resection time (4.0 versus 7.5 minutes, P < 0.001). The rate of WIT >25 minutes decreased (6.3% versus 25%, P = .04) and the trifecta outcomes were significantly improved (87.5% versus 62.5%, P = .02). Conclusion Internal suspension technique is a feasible and safe procedure in retroperitoneal laparoscopic partial nephrectomy for renal ventral tumors.
Collapse
|
32
|
Chien YC, Chiang HC, Huang SH, Wang BF. Self-retaining barbed suture during laparoscopic partial nephrectomy. UROLOGICAL SCIENCE 2017. [DOI: 10.1016/j.urols.2015.12.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
33
|
Jelley CR, Kurukulaarachchi KASH, Forster L, Bardgett H, Singh R, Addla SK. Comparison of open and robotic nephron sparing surgery: a single centre experience. JOURNAL OF CLINICAL UROLOGY 2017. [DOI: 10.1177/2051415816668942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective: To compare robotic partial nephrectomy (RAPN) with open partial nephrectomy (OPN) to assess efficacy and impact of learning curve. Methods: From 2010 to 2015 159 patients had a partial nephrectomy (82 OPN and 77 RAPN). All data were collected prospectively. We compared the demographics, peri and postoperative outcomes. Results: Mean age was 60 years in both groups; 59% of patients were men. Tumour size was larger in the open group (34 mm vs 30 mm; P<0.08), but RENAL nephrometry scores greater than 6 were comparable (over 60%). Mean ischaemic time was longer in the RAPN group (18 vs 13 minutes; P<0.04) but complication rates were similar. The RAPN cohort had a reduced estimated blood loss (100 ml vs 300 ml; P<0.01) and shorter median hospital stay (2 vs 5 days; P<0.01). Only two patients in each group were margin positive. The RAPN cohort demonstrated reduced estimated blood loss and a trend towards more complex tumours with increasing learning curve. Conclusion: RAPN is superior to OPN in terms of reduced hospital stay and estimated blood loss without compromising oncological outcomes. This service can be delivered safely and effectively in a low to medium volume cancer centre; these results are similar to published figures from high volume international centres.
Collapse
Affiliation(s)
| | | | - Luke Forster
- Department of Urology, Bradford Royal Infirmary, UK
| | | | | | - Sanjai K Addla
- Department of Urology, Bradford Royal Infirmary, UK
- Apollo Cancer Institutes, Apollo Health City, Jubilee Hills, Hyderabad, India
| |
Collapse
|
34
|
Kramer MW, Merseburger AS, Hoda R. Surgical Methods in Treatment of Kidney Tumors: Open Surgery Versus Laparoscopy Versus Robotic Surgery. Urol Oncol 2017. [DOI: 10.1007/978-3-319-42603-7_63-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
|
36
|
Banegas MP, Harlan LC, Mann B, Yabroff KR. Toward greater adoption of minimally invasive and nephron-sparing surgical techniques for renal cell cancer in the United States. Urol Oncol 2016; 34:433.e9-433.e17. [PMID: 27321355 PMCID: PMC5035195 DOI: 10.1016/j.urolonc.2016.05.021] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2015] [Revised: 03/22/2016] [Accepted: 05/16/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE To examine national, population-based utilization trends of nephron-sparing and minimally invasive techniques for the surgical management of patients with adult renal cell cancer (RCC) in the United States. METHODS Linked data from the National Cancer Institute׳s Patterns of Care studies and the Area Health Resource File were used to evaluate trends of nephron-sparing and minimally invasive techniques in a sample of 1,110 patients newly diagnosed with American Joint Committee on Cancer stages I-II RCC, in 2004 and 2009, who underwent surgery. Descriptive statistics were used to assess patterns of surgery between 2004 and 2009. Multivariable logistic regression analyses were used to evaluate the associations between demographic, clinical, hospital, and area-level health care characteristics with surgery utilization, stratified by the subset of patients who were potentially eligible for partial nephrectomy (PN) vs. radical nephrectomy (RN) and laparoscopic RN (LRN) vs. open RN, respectively. RESULTS Between 2004 and 2009, PN use among stage I patients with tumors≤7cm increased from 29% to 41%, respectively (P = 0.22). Among patients with stage I tumors≤4cm, use of PN significantly increased from 43% in 2004 to 55% in 2009 (P≤0.05). Among patients with stage I tumors>4 to 7cm, laparoscopic partial nephrectomy increased from 8% to 15%, whereas LRN increased from 38% to 69%, between 2004 and 2009 (P = 0.07). Significant increases in LRN use were observed for both stage I (from 43% in 2004 to 58% in 2009; P≤0.05) and stage II patients (from 16% in 2004 to 47% in 2009; P≤0.01). Patients diagnosed at an older age, with larger tumors, non-clear cell RCC and who did not receive treatment in a hospital with residency training were significantly less likely to receive PN vs. RN; whereas, those diagnosed in 2009 with stage I disease were significantly more likely to receive LRN vs. open RN. CONCLUSIONS This study highlights a significant shift toward increased use of nephron-sparing and minimally invasive surgical techniques to treat patients with RCC in the United States. Our findings are among the first population-based reports in which most eligible patients with RCC received PN over RN. In light of the long-standing evidence on the improved patient outcomes, future investigation is warranted to identify the barriers to increased adoption of these nephron-sparing and minimally invasive approaches.
Collapse
Affiliation(s)
- Matthew P Banegas
- Kaiser Permanente Northwest, The Center for Health Research, Portland, OR.
| | - Linda C Harlan
- Healthcare Assessment Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
| | - Bhupinder Mann
- Clinical Investigations Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
| | - K Robin Yabroff
- Healthcare Assessment Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
| |
Collapse
|
37
|
Rassweiler JJ, Klein J, Tschada A, Gözen AS. Laparoscopic retroperitoneal partial nephrectomy using an ergonomic chair: demonstration of technique and matched-pair analysis. BJU Int 2016; 119:349-357. [DOI: 10.1111/bju.13627] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Jens J. Rassweiler
- Department of Urology; SLK Kliniken Heilbronn; University of Heidelberg; Heilbronn Germany
| | - Jan Klein
- Department of Urology; SLK Kliniken Heilbronn; University of Heidelberg; Heilbronn Germany
| | - Alexandra Tschada
- Department of Urology; SLK Kliniken Heilbronn; University of Heidelberg; Heilbronn Germany
| | - Ali Serdar Gözen
- Department of Urology; SLK Kliniken Heilbronn; University of Heidelberg; Heilbronn Germany
| |
Collapse
|
38
|
Vitagliano G, Lopez F, Guglielmi JM, Mieggi M, Blas L, Rico L, Ameri C. Synthetic Renal Capsule Tailoring: A Novel Renorrhaphy Technique After Subcapsular Dissection of Renal Tumors with Severe Adherent Perirenal Fat During Laparoscopic Partial Nephrectomy. J Laparoendosc Adv Surg Tech A 2016; 27:717-721. [PMID: 27455068 DOI: 10.1089/lap.2016.0318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Multiple factors can account for surgical complexity during laparoscopic partial nephrectomy (LPN); severe adhesion of perirenal fat (PRF) is a crucial one. Consequent renal decapsulation can deem renorrhaphy a very challenging task. We propose a novel technique (synthetic renal capsule tailoring [SYRCT]) to facilitate renorrhaphy in decapsulated kidneys and suggest early decapsulation as a safe option in cases with severe PRF. MATERIALS AND METHODS We retrospectively analyzed perioperative results of this novel technique performed in cases with severe PRF. All cases were classified as high grade in the Mayo Adhesive Probability (MAP) score. RESULTS A total of six cases were performed with the SYRCT technique. All patients were male with a mean age of 70 years (62-76 years) and mean body mass index of 30 kg/m2 (23.66-33.86). Of the six cases, five were T1a and 1 T1b. Mean tumor size was 2.83 cm (range 1.2-6 cm). Mean operative time was 121 minutes (range 74-150 minutes); mean warm ischemia time was 17.2 minutes (range 13-25 minutes). Mean operative bleeding was 128 mL (range 50-250 mL). Mean hospital stay was 2.3 days. There were no surgical complications greater or equal to Clavien II. CONCLUSION Performing complete renal decapsulation with subcapsular dissection and SYRCT in cases with high MAP score and severe PRF is safe and reproducible. Using this novel technique, we were able to obtain perioperative results comparable to the ones we found in LPN with normal PRF.
Collapse
Affiliation(s)
- Gonzalo Vitagliano
- Urolaparoscopic Section, Department of Urology, Hospital Alemán , Buenos Aires, Argentina
| | - Francisco Lopez
- Urolaparoscopic Section, Department of Urology, Hospital Alemán , Buenos Aires, Argentina
| | - Juan Manuel Guglielmi
- Urolaparoscopic Section, Department of Urology, Hospital Alemán , Buenos Aires, Argentina
| | - Mauro Mieggi
- Urolaparoscopic Section, Department of Urology, Hospital Alemán , Buenos Aires, Argentina
| | - Leandro Blas
- Urolaparoscopic Section, Department of Urology, Hospital Alemán , Buenos Aires, Argentina
| | - Luis Rico
- Urolaparoscopic Section, Department of Urology, Hospital Alemán , Buenos Aires, Argentina
| | - Carlos Ameri
- Urolaparoscopic Section, Department of Urology, Hospital Alemán , Buenos Aires, Argentina
| |
Collapse
|
39
|
Peyronnet B, Seisen T, Oger E, Vaessen C, Grassano Y, Benoit T, Carrouget J, Pradère B, Khene Z, Giwerc A, Mathieu R, Beauval JB, Nouhaud FX, Bigot P, Doumerc N, Bernhard JC, Mejean A, Patard JJ, Shariat S, Roupret M, Bensalah K. Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors. Ann Surg Oncol 2016; 23:4277-4283. [DOI: 10.1245/s10434-016-5411-0] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2016] [Indexed: 01/20/2023]
|
40
|
Alghamdi A, Alkhateeb S, Alghamdi K, Bazarbashi S, Murshid E, Alotaibi M, Abusamra A, Rabah D, Ahmad I, Al-Mansour M, Saadeddin A, Alsharm A. Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma. Urol Ann 2016; 8:136-140. [PMID: 27141180 PMCID: PMC4839227 DOI: 10.4103/0974-7796.179239] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Accepted: 11/15/2015] [Indexed: 02/05/2023] Open
Abstract
This is an update to the previously published Saudi guidelines for the evaluation, medical, and surgical management of patients diagnosed with renal cell carcinoma (RCC). It is categorized according to the stage of the disease using the tumor node metastasis staging system 7(th) edition. The guidelines are presented with supporting evidence level, they are based on comprehensive literature review, several internationally recognized guidelines, and the collective expertise of the guidelines committee members (authors) who were selected by the Saudi Oncology Society and Saudi Urological Association. Considerations to the local availability of drugs, technology, and expertise have been regarded. These guidelines should serve as a roadmap for the urologists, oncologists, general physicians, support groups, and healthcare policy makers in the management of patients diagnosed with RCC.
Collapse
Affiliation(s)
- Abdullah Alghamdi
- Department of Urology, Prince Sultan Military Medical City, Jeddah, Saudi Arabia
| | - Sultan Alkhateeb
- Department of Surgery, Division of Urology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Khalid Alghamdi
- Department of Surgery, Division of Urology, Security Forces Hospital, Riyadh, Saudi Arabia
| | - Shouki Bazarbashi
- Department of Oncology, Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Esam Murshid
- Department of Oncology, Oncology Center, Prince Sultan Military Medical City, Jeddah, Saudi Arabia
| | - Mohammed Alotaibi
- Department of Urology, King Faisal Specialist Hospital and Research Center, RIyadh, Saudi Arabia
| | - Ashraf Abusamra
- Department of Surgery, Urology Section, King Khalid Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
| | - Danny Rabah
- Department of Surgery, College of Medicine and Uro-Oncology Research Chair, King Saud University, Riyadh, Saudi Arabia
| | - Imran Ahmad
- Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mubarak Al-Mansour
- Department of Oncology, King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
| | - Ahmad Saadeddin
- Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia
| | - Abdullah Alsharm
- Department of Medical Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia
| |
Collapse
|
41
|
Meyer C, Hansen J, Becker A, Schmid M, Pradel L, Strini K, Chromecki T, Jesche-Chromecki J, Fisch M, Zigeuner R, Chun FKH. The Adoption of Nephron-Sparing Surgery in Europe - A Trend Analysis in Two Referral Centers from Austria and Germany. Urol Int 2015; 96:330-6. [PMID: 26699625 DOI: 10.1159/000442215] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 11/04/2015] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To compare the trends of partial nephrectomy (PN) and radical nephrectomy (RN) in 2 European tertiary referral centers with regards to guideline changes. MATERIALS AND METHODS A total of 1,573 patients who underwent RN or PN for localized (≤T2) renal cell carcinoma (RCC) were included. Logistic regression analyses assessed the predictors of PN and laparoscopy over time. RESULTS Out of the total, 1,013 patients (65.6%) were treated with RN and 560 patients (34.4%) with PN. Also, 1,233 patients (80%) had open surgery whereas 340 patients (22%) were treated with a laparoscopic approach. Laparoscopic RN and PN were performed in 216 (13.7%) and 124 (7.8%) patients, respectively. T1b tumors were 73% less likely (p < 0.001) to be treated with PN compared to T1a tumors. The odds of undergoing PN or laparoscopy in 2008-2010 relative to 2000-2001 were 6.5-fold (p < 0.001) and 36-fold higher (p < 0.001), respectively. CONCLUSIONS Tumor size and year of surgery are independent predictors of PN in our cohort. Our data exemplify the adoption of PN for RCC in tertiary care centers in Austria and Germany in line with implemented guideline changes. The utilization of PN has increased over time regardless of surgical approach. Further studies need to address the use of robot-assisted surgery and care in community hospitals.
Collapse
Affiliation(s)
- Christian Meyer
- Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Zhang C, Li X, Yu W, Zhang Q, Zhou L, He Z. Ring Suture Technique in Retroperitoneal Laparoscopic Partial Nephrectomy for Hilar Cancer: A New Renorrhaphy Technique. J Endourol 2015; 30:390-4. [PMID: 26577028 DOI: 10.1089/end.2015.0691] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND AND PURPOSE To evaluate the safety and efficacy of a ring suture technique during retroperitoneal laparoscopic partial nephrectomy (RLPN) for management of renal cell carcinoma (RCC) in the renal hilum. PATIENTS AND METHODS Data for patients with renal hilar cancer who underwent RLPN from January 2010 to March 2015 were collected. All surgeries involved the ring suture technique, following the same procedure: the renal artery was dissected and clamped, the tumor was enucleated from the kidney, defects of the vascular and collecting system were repaired, and then the edge of the renal parenchyma was sutured continuously along the border. Finally, the renal artery clamp was removed, and any injury of the vascular system was repaired if necessary. We retrospectively analyzed renal ischemic time, blood loss, and postoperative complications. RESULTS Among the 17 patients, 11 were male (median age 61 years, range 42-71 years). Mean tumor diameter was 3.4 ± 0.9 cm and median R.E.N.A.L. nephrometry score was 8 (range 6-10). The mean warm ischemic time was 23.0 ± 9.2 minutes and median blood loss during surgery was 110 mL (range 70-350 mL); we had no case of uncontrollable massive bleeding. Radical nephrectomy was used in one case because of tumor embolus in a branch of the renal vein. All patients recovered well following surgery. Pathology confirmed the diagnosis of RCC in all cases, with the main subtype clear-cell carcinomas (88.2%). CONCLUSIONS The ring suture technique is safe and effective for management of renal hilar cancer during RLPN for selected patients.
Collapse
Affiliation(s)
- Cuijian Zhang
- 1 Department of Urology, Peking University First Hospital , Beijing, China .,2 Institute of Urology, Peking University , Beijing, China .,3 National Urological Cancer Center , Beijing, China
| | - Xuesong Li
- 1 Department of Urology, Peking University First Hospital , Beijing, China .,2 Institute of Urology, Peking University , Beijing, China .,3 National Urological Cancer Center , Beijing, China
| | - Wei Yu
- 1 Department of Urology, Peking University First Hospital , Beijing, China .,2 Institute of Urology, Peking University , Beijing, China .,3 National Urological Cancer Center , Beijing, China
| | - Qian Zhang
- 1 Department of Urology, Peking University First Hospital , Beijing, China .,2 Institute of Urology, Peking University , Beijing, China .,3 National Urological Cancer Center , Beijing, China
| | - Liqun Zhou
- 1 Department of Urology, Peking University First Hospital , Beijing, China .,2 Institute of Urology, Peking University , Beijing, China .,3 National Urological Cancer Center , Beijing, China
| | - Zhisong He
- 1 Department of Urology, Peking University First Hospital , Beijing, China .,2 Institute of Urology, Peking University , Beijing, China .,3 National Urological Cancer Center , Beijing, China
| |
Collapse
|
43
|
Shiroki R, Fukami N, Fukaya K, Kusaka M, Natsume T, Ichihara T, Toyama H. Robot-assisted partial nephrectomy: Superiority over laparoscopic partial nephrectomy. Int J Urol 2015; 23:122-31. [DOI: 10.1111/iju.13001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 09/23/2015] [Indexed: 02/06/2023]
Affiliation(s)
- Ryoichi Shiroki
- Department of Urology; Fujita Health University School of Medicine; Toyoake Aichi Japan
| | - Naohiko Fukami
- Department of Urology; Fujita Health University School of Medicine; Toyoake Aichi Japan
| | - Kosuke Fukaya
- Department of Urology; Fujita Health University School of Medicine; Toyoake Aichi Japan
| | - Mamoru Kusaka
- Department of Urology; Fujita Health University School of Medicine; Toyoake Aichi Japan
| | - Takahiro Natsume
- Faculty of Radiological Technology; Fujita Health University School of Health Sciences; Toyoake Aichi Japan
| | - Takashi Ichihara
- Faculty of Radiological Technology; Fujita Health University School of Health Sciences; Toyoake Aichi Japan
| | - Hiroshi Toyama
- Department of Radiology; Fujita Health University School of Medicine; Toyoake Aichi Japan
| |
Collapse
|
44
|
Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A. Chinese guidelines on the management of renal cell carcinoma (2015 edition). ANNALS OF TRANSLATIONAL MEDICINE 2015; 3:279. [PMID: 26697439 PMCID: PMC4671863 DOI: 10.3978/j.issn.2305-5839.2015.11.21] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Accepted: 11/04/2015] [Indexed: 02/05/2023]
Affiliation(s)
- Jun Guo
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Jianhui Ma
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Yan Sun
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Shukui Qin
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Dingwei Ye
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Fangjian Zhou
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Zhisong He
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Xinan Sheng
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Feng Bi
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Dengfeng Cao
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Yingxia Chen
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Yiran Huang
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Houjie Liang
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Jun Liang
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Jiwei Liu
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Wenchao Liu
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Yueyin Pan
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Yongqian Shu
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Xin Song
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Weibo Wang
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Xiuwen Wang
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Xiaoan Wu
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Xiaodong Xie
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Xin Yao
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Shiying Yu
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Yanqiao Zhang
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Aiping Zhou
- 1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China ; 3 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 4 Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China ; 5 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 6 Peking University Institute of Urology & Peking University First Hospital, Beijing 100034, China ; 7 West China Hospital of Sichuan University, Chengdu 610041, China ; 8 Washington University School of Medicine, St. Louis, USA ; 9 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200135, China ; 10 Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; 11 Peking University International Hospital, Beijing 100142, China ; 12 The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 13 Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China ; 14 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 15 Jiangsu Province Hospital & First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China ; 16 Yunnan Provincial Cancer Hospital, Kunming 650118, China ; 17 Shandong Provincial Hospital, Jinan 250012, China ; 18 Qilu Hospital of Shandong University, Jinan, China ; 19 PLA 174 Hospital & Nanjing Military Region Cancer Center, Xiamen 361003, China ; 20 General Hospital of Shenyang Military Command, Shenyang 110016, China ; 21 Cancer Hospital Affiliated to Tianjin Medical University, Tianjin 300060, China ; 22 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ; 23 Cancer Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | | | | |
Collapse
|
45
|
The management of small renal masses: what is likely to change? Urologia 2015. [PMID: 26219473 DOI: 10.5301/uro.5000127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The diffusion of imaging has determined an increased discovery of small renal masses (SRMs). Recent publications have been reviewed to present the state of the art in the management of SRMs and to try to foresee the next steps in this challenging condition. The role of percutaneous biopsies is expanding, since management algorithms include also active surveillance and ablative therapies. However up to 30% of biopsies fail to provide histological diagnosis and there is the risk of under-evaluating high-grade tumors. Active surveillance has been proposed in patients with reduced life expectancy and numerous comorbidities. The average growth of SRMs is slow, and metastatic progression has been observed in about 1%. Ablative therapies (cryotherapy and radiofrequency ablation) are used in patients with relevant comorbidities or advanced age and unfit for surgery, but who desire active treatment. Compared to conservative surgical treatment both techniques have increased local progression rates, while metastatic progression is relatively low.Partial nephrectomy (PN) is the recommended curative treatment for SRMs and can be performed open, laparoscopically or robotically. Open PN represents the benchmark, with similar cancer specific survival and better preservation of renal function compared to nephrectomy. Laparoscopy is comparable to open surgery in terms of oncologic results, but a long learning curve is necessary. Perioperative outcomes of robot-assisted PN appear superior to laparoscopy and the learning curve is shorter, but data for oncological results are still immature. With the increasing diffusion of robotic technology it is likely more SRMs will be managed with this approach.
Collapse
|
46
|
Harel M, Herbst KW, Silvis R, Makari JH, Ferrer FA, Kim C. Objective pain assessment after ureteral reimplantation: comparison of open versus robotic approach. J Pediatr Urol 2015; 11:82.e1-8. [PMID: 25864615 DOI: 10.1016/j.jpurol.2014.12.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Accepted: 12/18/2014] [Indexed: 12/26/2022]
Abstract
INTRODUCTION While open ureteral reimplantation is the gold standard of surgical intervention for vesicoureteral reflux (VUR), minimally invasive approaches offer the potential benefits of decreased postoperative pain, improved cosmesis, and shorter hospital stay and convalescence. Studies comparing open and minimally invasive surgery with respect to postoperative pain in children have been inconclusive. OBJECTIVE We sought to compare postoperative pain in children undergoing open versus robotic ureteral reimplantation by using age-appropriate, validated pain assessment scales. METHODS A prospective cohort of all patients enrolled in an Institutional Review Board-approved VUR surgery registry between July 2010 and February 2013 was analyzed. Patients who underwent endoscopic treatment or who received caudal or epidural anesthesia were excluded. Age-appropriate, validated pain scales ranging from 0 to 10 were utilized for pain assessment. Pain scores and narcotic doses administered on the first postoperative day were analyzed. RESULTS Of the 34 subjects included, 11 underwent open intravesical reimplantation, while 23 patients underwent robotic extravesical reimplantation. Table 1 displays patient characteristics and results of pain assessment. Robotic surgery was associated with lower narcotic requirement compared to open surgery (P < 0.05). The difference in pain scores between the two cohorts approached, but did not reach, statistical significance (P = 0.12). However, the percentage of patients with mild or no pain (57% robotic, 27% open) versus severe pain (9% robotic, 45% open) was notably different between the two cohorts. DISCUSSION Previous studies addressing the effect of surgical modality on pediatric postoperative pain are limited by their reliance on narcotic administration as an indirect surrogate for measuring pain. In the present study, postoperative pain was assessed with narcotic requirements and consistently collected validated pain scores, which more accurately reflect a patient's perceived pain. Although there was no significant difference in subjective pain scores between patients undergoing open versus robotic reimplantation, the percentage of patients with mild or no pain (57% robotic, 27% open) versus severe pain (9% robotic, 45% open) was notably different between the two cohorts. This study was limited by a lack of randomization as well as small sample size, which did not allow for age sub-group analysis or small differences to be statistically significant. CONCLUSIONS In the present study, robotic ureteral reimplantation was associated with lower narcotic requirement compared to open surgery, and lower intensity of postoperative pain according to a direct pain assessment tool. Larger sample sizes are necessary to strengthen statistical comparisons.
Collapse
Affiliation(s)
- M Harel
- University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
| | - K W Herbst
- Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
| | - R Silvis
- Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
| | - J H Makari
- University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
| | - F A Ferrer
- University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
| | - C Kim
- University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
| |
Collapse
|
47
|
Wang K, Zhang YL, Lin CH, Liu DF, Men CP, Wang JM, Gao ZL. Application of self-retaining bidirectional barbed absorbable suture in retroperito- neoscopic partial nephrectomy. Int Braz J Urol 2014; 40:220-4. [PMID: 24856489 DOI: 10.1590/s1677-5538.ibju.2014.02.12] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Accepted: 07/25/2013] [Indexed: 11/22/2022] Open
Abstract
OBJECTIVE To investigate the safety and feasibility of self-retaining bidirectional barbed absorbable suture application in retroperitoneoscopic partial nephrectomy. MATERIALS AND METHODS From Sep 2011 and Aug 2012, 76 cases of retroperitoneoscopic partial nephrectomy were performed at our hospital. The patients were divided into two groups: self-retaining barbed suture (SRBS) group (n = 36) and non-SRBS group (n = 40). There was no significant difference in age, sex, tumor size and location between the two groups. Clinical data and outcomes were analyzed retrospectively. RESULTS All 76 cases of retroperitoneoscopic partial nephrectomy were successfully performed, without conversion to open surgery or serious intraoperative complications. In the SRBS group, the suture time, warm ischemia time and operation blood loss were significantly shorter than that of non-SRBS group (p < 0.01), and operation time and hospital stay were shorter than that of non-SRBS group (p < 0.05). CONCLUSIONS The application of self-retaining bidirectional barbed absorbable suture in retroperitoneoscopic partial nephrectomy could shorten suture time and warm ischemia time, with good safety and feasibility, worthy of being used in clinic.
Collapse
Affiliation(s)
- Ke Wang
- Department of Urology, Yantai Yuhuangding Hospital , Yantai 264000, China
| | - Yu-Lian Zhang
- Department of Gynecology (ZYL), Yantai Yuhuangding Hospital , Yantai 264000, China
| | - Chun-Hua Lin
- Department of Urology, Yantai Yuhuangding Hospital , Yantai 264000, China
| | - Dong-Fu Liu
- Department of Urology, Yantai Yuhuangding Hospital , Yantai 264000, China
| | - Chang-Ping Men
- Department of Urology, Yantai Yuhuangding Hospital , Yantai 264000, China
| | - Jian-Ming Wang
- Department of Urology, Yantai Yuhuangding Hospital , Yantai 264000, China
| | - Zhen-Li Gao
- Department of Urology, Yantai Yuhuangding Hospital , Yantai 264000, China
| |
Collapse
|
48
|
Robotic partial nephrectomy: our first 30 consecutive cases. J Robot Surg 2014. [DOI: 10.1007/s11701-014-0476-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
49
|
A Single Surgeon's Experience with Open, Laparoscopic, and Robotic Partial Nephrectomy. INTERNATIONAL SCHOLARLY RESEARCH NOTICES 2014; 2014:430914. [PMID: 27379266 PMCID: PMC4897561 DOI: 10.1155/2014/430914] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/13/2014] [Revised: 09/07/2014] [Accepted: 09/07/2014] [Indexed: 01/20/2023]
Abstract
Objective. To report the perioperative outcomes of patients treated with partial nephrectomy by a single surgeon using three surgical modalities-open, laparoscopic, and robotic. Methods. Between August 2006 and February 2012, 106 consecutive patients underwent open partial nephrectomy (OPN) (n = 23), laparoscopic partial nephrectomy (LPN) (n = 48), and robotic partial nephrectomy (RPN) (n = 35) by a single surgeon. Clinical variables, operative parameters, and renal functional outcomes were analyzed. Results. Preoperative patient characteristics were similar except for baseline glomerular filtration rate (GFR), which was highest in the RPN group (P = 0.004). Surgery time was longest in the RPN group (244 minutes) and shortest in the OPN group (163 minutes, P < 0.0001). Patients who had OPN had the highest incidence of 30-day complications (30%), while the RPN approach had the lowest (14%, P = 0.008). Conclusions. When performed by a single surgeon, robotic partial nephrectomy appears to be associated with fewer complications than both open and laparoscopic partial nephrectomy. Kidney function was not affected by surgical approach.
Collapse
|
50
|
Bazarbashi S, Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Almansour M, Murshid E, Alsharm A, Alolayan A, Ahmad I, Alghamdi K, Alghamdi A. Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma. Urol Ann 2014; 6:286-289. [PMID: 25371602 PMCID: PMC4216531 DOI: 10.4103/0974-7796.140974] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Accepted: 04/15/2014] [Indexed: 02/05/2023] Open
Abstract
In this report, updated guidelines for the evaluation, medical and surgical management of renal cell carcinoma are presented. They are categorized according the stage of the disease using the tumor node metastasis staging system 7(th) edition. The recommendations are presented with supporting evidence level.
Collapse
Affiliation(s)
| | - Sultan Alkhateeb
- Department of Surgery, Division of Urology, Riyadh, Saudi Arabia
| | - Ashraf Abusamra
- Section of Urology, Department of Surgery, King Khaled Hospital, Riyadh, Saudi Arabia
| | - Danny Rabah
- Department of Surgery, Division of Urology, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia
- Princess Al-Johora Al-Ibrahim Centre for Cancer Research (Uro-Oncology Research Chair), King Saud University, Riyadh, Saudi Arabia
| | - Mohammed Alotaibi
- Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Mubarak Almansour
- Oncology Department, Princess Noura Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia
| | - Esam Murshid
- Department of Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Abdullah Alsharm
- Department of Oncology, King Fahad Medical City, Riyadh, Saudi Arabia
| | - Ashwaq Alolayan
- Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia
| | - Imran Ahmad
- Department of Oncology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
| | - Khalid Alghamdi
- Department of Surgery, Division of Urology, Security Forces Hospital, Riyadh, Saudi Arabia
| | - Abdullah Alghamdi
- Department of Urology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| |
Collapse
|